XNAS · Laboratory Analytical Instruments · S&P 500
$32.91
+$0.59 (+1.83%) today
Open $32.32 High $33.21 Low $31.99 Vol 188K Avg $32.79
Find similar stocks by technical condition — S&P 500 universe
| Symbol | Company Name | Exchange | Currency | Category |
|---|---|---|---|---|
| AMS | American Shared Hospital Services | XASE | USD | SERVICES-MEDICAL LABORATORIES |
| SERA | Sera Prognostics, Inc. Class A Common Stock | XNAS | USD | SERVICES-MEDICAL LABORATORIES |
| ADVB | Advanced Biomed Inc. Common Stock | XNAS | USD | SERVICES-MEDICAL LABORATORIES |
| CSTL | Castle Biosciences, Inc. Common Stock | XNAS | USD | SERVICES-MEDICAL LABORATORIES |
| ACON | Aclarion, Inc. Common Stock | XNAS | USD | SERVICES-MEDICAL LABORATORIES |
| XGN | Exagen Inc. Common Stock | XNAS | USD | SERVICES-MEDICAL LABORATORIES |
52-week price range
Price is 85.7% above its 52-week low and 25.7% below its 52-week high. Trading in the upper half of its annual range — closer to the peak than the base.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.